Cerecor, Inc.

( )
CERC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
AMRNAmarin Corp. Plc 2.57%13.581.6%$124.95m
JAZZJazz Pharmaceuticals Plc 2.72%99.602.3%$96.71m
PRGOPerrigo Co. Plc 5.77%48.766.8%$95.77m
VRXValeant Pharmaceuticals International, Inc. 5.10%15.2514.1%$89.73m
UTHRUnited Therapeutics Corp. 6.30%97.0714.3%$74.65m
CTLTCatalent, Inc. 3.27%50.522.2%$74.38m
ICLRICON plc 4.08%140.554.2%$68.13m
AXSMAxsome Therapeutics, Inc. -8.99%57.581.9%$63.59m
HZNPHorizon Therapeutics Plc 6.61%29.356.5%$60.68m
GWPHGW Pharmaceuticals Plc -0.67%85.186.2%$59.80m
ICPTIntercept Pharmaceuticals, Inc. -0.06%65.0316.8%$45.37m
SAGESAGE Therapeutics, Inc. -6.35%29.508.6%$44.64m
ZGNXZogenix, Inc. 9.50%25.589.2%$39.79m
PCRXPacira Biosciences, Inc. 6.24%33.7110.4%$33.15m
PBHPrestige Consumer Healthcare, Inc. 2.09%37.164.0%$32.37m

Company Profile

Cerecor, Inc. engages in the development and commercialization of treatments for rare pediatric and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.